A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented <i>Candida</i> or <i>Aspergillus</i> Infections in Pediatric Patients

Abstract

Caspofungin was generally well tolerated in pediatric patients aged 6 months through 17 years. Efficacy outcomes in patients with invasive aspergillosis or invasive candidiasis were consistent with previous adult studies in these indications.